Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entacapone and Imatinib in GIST after Imatinib and Sunitinib Failure
NCT04006769Phase 1Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Oct 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entacapone in gastrointestinal stromal tumor (GIST), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Adverse Events and Serious Adverse Events at 36 months. Started Oct 2020; status: completed.
02
Drugs
entacapone
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04006769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006769.